<DOC>
	<DOCNO>NCT02266524</DOCNO>
	<brief_summary>To investigate pharmacokinetics , safety , tolerability tamsulosin hydrochloride child void disorder</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Tamsulosin Hydrochloride Children With Voiding Disorders</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Urination Disorders</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Boys girl ( history ) void disorder Age : 5 15 year Body weight height ≥ 5 % ≤95 % normal use nomogram Signed date write informed consent parent guardian , appropriate , informed assent child , prior admission study accordance good clinical practice ( GCP ) local legislation , obtain Clinically significant abnormality find , randomization Visit 2 [ i.e. , abnormal : vital sign ( e.g. , hypotension ) , ECGs , well significant finding physical examination ] , determine investigator Clinically relevant condition include , limited , follow : gastrointestinal , cardiovascular ( e.g. , subject fall 90th percentile accord blood pressure nomogram ISF ) , hepatic , renal , hematologic , metabolic ( include diabetes mellitus ) , immunological , hormonal disorder , respiratory disease cancer Subjects surgery within last 30 day Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder Subjects neurological impairment psychiatric disorder prevents comprehension consent ability comply protocol History relevant orthostatic hypotension , faint spell blackout . Postdural symptom occur ( e.g. , lightheadedness , dizziness , faint ) without change blood pressure / pulse rate within 6 week Visit 2 Relevant acute infection , especially regard urinary tract infection active genitourinary infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Subjects know hypersensitivity FLOMAX® ( tamsulosin hydrochloride ) alphablockers Use medication classify cytochrome P450 3A4 ( CYP3A4 ) inhibitors inducer within 10 day prior administration trial drug Intake drug long halflife ( &gt; 24 hour ) within less 10 halflives respective drug prior administration Participation another trial investigational drug within 1 month prior administration trial Inability comply dietary regimen study center Pregnancy subject breast feed All subject parent guardian investigator 's opinion understand term inform consent form subject information</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>